GlaxoSmithKline, Britain’s biggest drugmaker, confirmed plans yesterday to invest more than ￡500 million (US$792 million) in manufacturing in Britain as it selected a north of England location for a previously announced biotech plant.
The news — though expected — is a boost for British Prime Minister David Cameron, who has made wooing the pharmaceuticals industry a priority in the wake of Pfizer’s decision last year to shutter its giant research center in Sandwich, southern England.
GSK had said on previous occasions it aimed to invest some ￡500 million and bring more jobs to Britain in response to government plans to cut the level of corporation tax applied to income from patents — a move known as a “patent box.”
The confirmation of its investment, which will create up to 1,000 jobs, comes the day after finance minister George Osborne’s budget in which he laid out business-friendly tax plans, including reiterating the patent box plan.
GSK said its new biopharmaceutical factory would be built in Ulverston, northern England, at a cost of ￡350 million, with construction expected to start in 2014 or 2015. The firm had looked at four possible UK sites.
At the same time GSK will invest more than ￡100 million in its two manufacturing sites in Scotland and the company is considering further investment at Ulverston which could double the total spending there to about ￡700 million.
Any further investment will depend on “continued improvements in the environment for innovation,” GSK said — a clear sign it intends to continue to put pressure on the government to make Britain a favorable place to do business.
In recent years the drugs industry has tended to put manufacturing in low-tax countries like Ireland and Singapore. However, introduction of the patent box has tipped the balance back, making Britain a viable choice once again.
The Ulverston facility will be GSK’s first new British factory for almost 40 years.
“The introduction of the patent box has transformed the way in which we view the UK as a location for new investments, ensuring that the medicines of the future will not only be discovered, but can also continue to be made here in Britain,” GSK chief executive Andrew Witty said.
DOLLAR CHALLENGE: BRICS countries’ growing share of global GDP threatens the US dollar’s dominance, which some member states seek to displace for world trade US president-elect Donald Trump on Saturday threatened 100 percent tariffs against a bloc of nine nations if they act to undermine the US dollar. His threat was directed at countries in the so-called BRICS alliance, which consists of Brazil, Russia, India, China, South Africa, Egypt, Ethiopia, Iran and the United Arab Emirates. Turkey, Azerbaijan and Malaysia have applied to become members and several other countries have expressed interest in joining. While the US dollar is by far the most-used currency in global business and has survived past challenges to its preeminence, members of the alliance and other developing nations say they are fed
LIMITED MEASURES: The proposed restrictions on Chinese chip exports are weaker than previously considered, following lobbying by major US firms, sources said US President Joe Biden’s administration is weighing additional curbs on sales of semiconductor equipment and artificial intelligence (AI) memory chips to China that would escalate the US crackdown on Beijing’s tech ambitions, but stop short of some stricter measures previously considered, said sources familiar with the matter. The restrictions could be unveiled as soon as next week, said the sources, who emphasized that the timing and contours of the rules have changed several times, and that nothing is final until they are published. The measures follow months of deliberations by US officials, negotiations with allies in Japan and the Netherlands, and
Foxconn Technology Group (富士康科技集團) yesterday said it expects any impact of new tariffs from US president-elect Donald Trump to hit the company less than its rivals, citing its global manufacturing footprint. Young Liu (劉揚偉), chairman of the contract manufacturer and key Apple Inc supplier, told reporters after a forum in Taipei that it saw the primary impact of any fresh tariffs falling on its clients because its business model is based on contract manufacturing. “Clients may decide to shift production locations, but looking at Foxconn’s global footprint, we are ahead. As a result, the impact on us is likely smaller compared to
TECH COMPETITION: The US restricted sales of two dozen types of manufacturing equipment and three software tools, and blacklisted 140 more Chinese entities US President Joe Biden’s administration unveiled new restrictions on China’s access to vital components for chips and artificial intelligence (AI), escalating a campaign to contain Beijing’s technological ambitions. The US Department of Commerce slapped additional curbs on the sale of high-bandwidth memory (HBM) and chipmaking gear, including that produced by US firms at foreign facilities. It also blacklisted 140 more Chinese entities that it accused of acting on Beijing’s behalf, although it did not name them in an initial statement. Full details on the new sanctions and Entity List additions were to be published later yesterday, a US official said. The US “will
RSS